Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax in Ph+ ALL
NCT05594784Phase 2Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib in Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Oct 2022; status: completed.
02
Drugs
olverembatinib
03
Conditions
Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT05594784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594784.